Citicoline has a decades-old but limited research history in Parkinson’s disease, specifically as an add-on to standard levodopa treatment rather than a replacement for it. This article covers what the actual trial evidence shows, and where it falls short of a settled answer.
Nothing here constitutes medical advice. Citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent any disease, and no one should adjust a Parkinson’s medication regimen without a treating physician.
Key Takeaways
- Citicoline has only been studied in Parkinson’s disease as an adjuvant to levodopa, never as a standalone treatment.
- A 1988 trial in 30 levodopa-treated patients found 500mg/day CDP-choline improved some neurologic signs and let researchers reduce levodopa by one-third without losing symptom control [1].
- That same trial saw increased dyskinesia during the full-dose levodopa phase, which normalized once the levodopa dose was reduced.
- Citicoline significantly raised plasma dopa and homovanillic acid levels, suggesting an effect on levodopa metabolism rather than independent dopamine activity [1][2].
- The evidence base is small, older, and short-duration; it points toward a plausible adjuvant role, not a proven or standard-of-care one.
Only Studied as an Add-On to Levodopa
Every piece of clinical evidence on citicoline in Parkinson’s disease comes from patients who were already established on levodopa therapy. The research question has consistently been whether adding citicoline changes levodopa’s effectiveness, side-effect profile, or required dose, not whether citicoline treats Parkinson’s on its own.
The Core Clinical Trial
The most-cited trial gave 30 Parkinson’s patients, all with a multi-year history of levodopa treatment, 500mg of cytidine diphosphate choline (CDP-choline, i.e., citicoline) daily for 30 days on top of their existing regimen. Researchers observed significant improvement in some neurologic signs and in electrophysiologic parameters measuring traction reflex and active muscle contraction, along with a more stable therapeutic response between levodopa doses. The tradeoff: dyskinesia (involuntary movements, a recognized levodopa complication) increased during this phase [1].
The Dose-Reduction Finding
In a second 30-day phase, researchers cut the levodopa dose by a third while keeping citicoline constant. The increased dyskinesia from the first phase dropped back down to its earlier level, and symptom control remained stable at the lower levodopa dose [1]. This is the most clinically interesting result in the trial: it suggests citicoline might let some patients maintain symptom control on a lower levodopa dose, which would be meaningful given levodopa’s own long-term side-effect burden. It’s a single small trial, though, not a finding replicated across multiple independent studies.
What the Metabolic Data Suggests
The trial also measured blood chemistry and found citicoline produced significant increases in plasma dopa and homovanillic acid (a downstream dopamine metabolite), with no change in tyrosine or 3-O-methyldopa [1]. Combined with an earlier proposal that CDP-choline could serve a biological role in Parkinson’s disease as a phospholipid precursor [2], this points toward citicoline influencing how the body processes levodopa itself, rather than citicoline acting as an independent Parkinson’s therapy.
The Honest Limits of This Evidence
This research area has real signal but real limitations: the foundational trial is small, from 1988, and each treatment phase lasted only 30 days. Longer-term safety, optimal dosing alongside levodopa, and which patients might benefit most haven’t been established through larger modern trials. Anyone with Parkinson’s disease considering citicoline should raise it with their neurologist rather than adding it independently, since levodopa dosing changes carry real clinical stakes.
Frequently Asked Questions
Is citicoline a treatment for Parkinson’s disease on its own?
No. The research on citicoline in Parkinson’s disease has tested it as an add-on (adjuvant) to standard levodopa therapy, not as a standalone treatment. Every trial in this area involved patients already being treated with levodopa.
What did the 1988 clinical trial actually find?
Thirty Parkinson’s patients already on long-term levodopa received 500mg of CDP-choline (citicoline) daily for 30 days alongside their existing medication. The trial found significant improvement in some neurologic signs and electrophysiologic measures of muscle contraction, plus greater stability in how patients responded between levodopa doses. However, the incidence of dyskinesia (involuntary movements, a known levodopa side effect) increased during this phase [1].
Did citicoline let patients reduce their levodopa dose?
In that same trial, researchers then reduced the levodopa dose by one-third while continuing citicoline. The increased dyskinesia dropped back to its earlier baseline level, and the therapeutic response to levodopa remained stable despite the lower dose [1]. This suggests citicoline may allow some dose reduction without losing symptom control, though this was one small trial, not a replicated finding.
Is there a proposed mechanism for why citicoline might help in Parkinson’s?
An earlier study framed CDP-choline as a phospholipid precursor with a biological rationale in Parkinson’s disease, and the 1988 trial found citicoline produced significant increases in plasma dopa and homovanillic acid (a dopamine metabolite), with no change in tyrosine or 3-O-methyldopa levels [1][2]. This points to citicoline affecting levodopa’s metabolism or dopamine pathway activity rather than acting as an independent dopaminergic agent.
How strong is this evidence overall?
Modest. The core trial is small (30 patients), over 35 years old, and short in duration (30 days per phase). A later systematic review of citicoline as Parkinson’s adjuvant therapy found 7 studies with varied methodology and concluded citicoline appeared to help reduce levodopa requirements and improve rigidity, akinesia, tremor, handwriting, and speech in some trials, but that the evidence base overall remains limited and needs larger, higher-quality trials. This is a promising but unsettled area of research, not an established standard of care.
References
- Cubells JM, Hernando C. Clinical trial on the use of cytidine diphosphate choline in Parkinson’s disease. Clinical Therapeutics (1988). PMID 3064905
- Agnoli A et al. New strategies in the management of Parkinson’s disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology (1982). PMID 7162583
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
